Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy

被引：4
|
作者：
Kallen, Michael E. [1 ]
Koka, Rima [1 ]
Singh, Zeba [1 ]
Sanchez-Petitto, Gabriela [2 ]
Zaman, Qamar U. [3 ]
Yared, Jean A. [2 ]
Duong, Vu H. [2 ]
机构：
[1] Univ Maryland, Sch Med, Dept Pathol, 22 S Greene St,NBW-54, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, Div Hematol Oncol, Baltimore, MD 21201 USA
[3] Univ Pittsburgh, Med Ctr, Western Maryland, Cumberland, MD USA
来源：
LEUKEMIA RESEARCH | 2020年 / 96卷
关键词：
DIFFERENTIATION SYNDROME;
D O I：
10.1016/j.leukres.2020.106406
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
    Wang, Fang
    Travins, Jeremy
    DeLaBarre, Byron
    Penard-Lacronique, Virginie
    Schalm, Stefanie
    Hansen, Erica
    Straley, Kimberly
    Kernytsky, Andrew
    Liu, Wei
    Gliser, Camelia
    Yang, Hua
    Gross, Stefan
    Artin, Erin
    Saada, Veronique
    Mylonas, Elena
    Quivoron, Cyril
    Popovici-Muller, Janeta
    Saunders, Jeffrey O.
    Salituro, Francesco G.
    Yan, Shunqi
    Murray, Stuart
    Wei, Wentao
    Gao, Yi
    Dang, Lenny
    Dorsch, Marion
    Agresta, Sam
    Schenkein, David P.
    Biller, Scott A.
    Su, Shinsan M.
    de Botton, Stephane
    Yen, Katharine E.
    SCIENCE, 2013, 340 (6132) : 622 - 626
  • [32] Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
    Atluri, Himachandana
    Maiti, Abhishek
    Sasaki, Koji
    Daver, Naval
    Alvarado, Yesid
    Hossain, Md Feroz
    Wang, Xuemei
    Pemmaraju, Naveen
    Takahashi, Koichi
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Short, Nicholas
    Abbas, Hussein A.
    Ravandi, Farhad
    Jabbour, Elias
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Konopleva, Marina
    DiNardo, Courtney D.
    BLOOD, 2022, 140 : 6170 - 6172
  • [33] Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
    Kats, Lev M.
    Reschke, Markus
    Taulli, Riccardo
    Pozdnyakova, Olga
    Burgess, Kerri
    Bhargava, Parul
    Straley, Kimberly
    Karnik, Rahul
    Meissner, Alexander
    Small, Donald
    Su, Shinsan M.
    Yen, Katharine
    Zhang, Jiangwen
    Pandolfi, Pier Paolo
    CELL STEM CELL, 2014, 14 (03) : 329 - 341
  • [34] Hitting the target in IDH2 mutant AML
    Wouters, Bas J.
    BLOOD, 2017, 130 (06) : 693 - 694
  • [35] IDH2 mutation in gliomas including novel mutation
    Koh, Jaemoon
    Cho, Hwajin
    Kim, Hannah
    Kim, Seong Ik
    Yun, Sumi
    Park, Chul-Kee
    Lee, Se-Hoon
    Choi, Seung Hong
    Park, Sung-Hye
    NEUROPATHOLOGY, 2015, 35 (03) : 236 - 244
  • [36] Critical Roles Of The IDH2 Mutation In Development and Maintenance Of Acute Myeloid Leukemia
    Ogawara, Yoko
    Katsumoto, Takuo
    Aikawa, Yukiko
    Shima, Yutaka
    Kagiyama, Yuki
    Matsunaga, Hironori
    Seki, Takahiko
    Kitabayashi, Issay
    BLOOD, 2013, 122 (21)
  • [37] Structural Biology of Mutant IDH2 Inhibition
    DeLaBarre, B.
    Wang, F.
    Travins, J.
    Gross, S.
    Artin, E.
    Dang, L.
    Biller, S.
    Yen, K.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2014, 70 : C799 - C799
  • [38] Rapid IDH1/IDH2 Mutation Assessment in Acute Myeloid Leukemia (AML) and Glioma
    Huynh, T.
    Zhang, L.
    Li, Y.
    Solis, J.
    Stanley, A.
    Jin, H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (11): : S163 - S164
  • [39] SECOND-SITE IDH2 MUTATIONS CONFER RESISTANCE TO ENASIDENIB IN TRANS
    不详
    CANCER DISCOVERY, 2018, 8 (08) : 913 - 913
  • [40] Infrequent IDH1 or IDH2 mutation in Glioblastoma
    Piao, Zhe
    Chhabra, Vaninder
    Tashjian, Vartan
    Goldenberg, Todd
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2016, 75 (06): : 584 - 584
12345